Prognostic genomic biomarkers that can be measured at diagnosis to aid choice of treatment options are unavailable for most common cancers. This is due in part to the poor quality and quantity of available diagnostic specimens for discovery research and to limitations in genomic technologies. Recent technical advances now enable high-density molecular analyses using suboptimal biological specimens. Here we describe the optimization of a transcriptome-specific protocol for use with formalin-fixed, paraffin-embedded (FFPE) diagnostic prostate cancer (PrCa) specimens. We applied the Ion AmpliSeq Transcriptome Human Gene Expression Kit (AmpliSeq Kit) to RNA samples extracted from 36 tumor-enriched and 16 adjacent normal tissues (ADJ NT ) from 37 FFPE PrCa specimens over a series of eight pilot studies, incorporating protocol modifications from Pilots 2 to 5. Data quality were measured by (1) the total number of mapped reads; (2) the percentage of reads that mapped to AmpliSeq target regions (OnTarget%); (3) the percentage of genes on the AmpliSeq panel with a read count ≥10 (TargetsDetected%); and (4) comparing the gene read-count distribution of the prostate tissue samples with the median gene read-count distribution of cell line-derived RNA samples. Modifications incorporated into Pilot study 5 provided gene expression data equivalent to cell line-derived RNA samples. These modifications included the use of freshly cut slides for macrodissection; increased tissue section thickness (8 µm); RNA extraction using the RecoverAll Total Nucleic Acid Isolation Kit for FFPE (ThermoFisher); 18 target amplification cycles; and processing six samples per Ion PI chip. This protocol will facilitate the discovery of prognostic biomarkers for cancer by allowing researchers to exploit previously underutilized diagnostic FFPE specimens.
PrCa is usually a needle biopsy fixed in formalin and embedded in paraffin (FFPE). Until recently, mRNA expression profiling involving these specimens has been limited due to the low quantity and poor quality of RNA available from this type of sample [12] .
Next-generation technologies can now be successfully applied to diagnostic FFPE material. These advances could facilitate the identification of a set of biomarkers that predict patient outcomes and inform treatment decisions. A recent study by Knudsen et al. analyzed 26 diagnostic PrCa FFPE biopsy specimens using the Affymetrix Human Exon 1.0 ST GeneChip [13] and demonstrated a high correlation between transcriptomic features in biopsies and matched RP specimens (r = 0.96). Here we describe the optimization and application of another gene expression platform, the Ion AmpliSeq™ Transcriptome Human Gene Expression Kit (AmpliSeq™ Kit; ThermoFisher Scientific), to 52 diagnostic PrCa FFPE specimens.
Materials and methods

Study cohorts
Tumor material for this study was identified from five epidemiological studies led by the Cancer Council Victoria, four of which have been described in detail previously: the Melbourne Collaborative Cohort Study (MCCS) [14, 15] ; the Risk Factors For Prostate Cancer Case-Control Study (RFPCS) [16, 17] ; the Early Onset Prostate Cancer Family Study (EOPCFS) [18] ; and the Radical Prostatectomy Registry [19] . The Aggressive Prostate Cancer (APC) study consists of Victorian men diagnosed with prostate cancer between 2 January 2010 and 25 January 2013 and agematched, PSA-screened and biopsy negative controls. Eligible cases were men diagnosed with high-grade tumors; i.e., Gleason score ≥7(4 + 3) and/or ≥T3 stage. Cases from all five studies were followed passively from date of diagnosis via linkage to the Victorian Registry of Births, Deaths, and Marriages, and the National Death Index, both of which obtained cause of death data from the Australian Bureau of Statistics. For this study, follow-up ended 31 March 2013, which was the latest date for which complete cause of death information was available at the time of specimen selection. Written informed consent was obtained from each participant and the study was approved by the Human Research Ethics Committee of the Cancer Council Victoria.
Study specimens
This study included pathology specimens from 22 MCCS cases, 11 RFPCS cases, 11 EOPCFS cases, four RPR cases, and four APC cases. For each case, FFPE diagnostic pathology material (a transrectal ultrasound (TRUS)-guided biopsy or transurethral resection (TURP) of the prostate) was retrieved from the diagnostic service laboratory and reviewed by an experienced pathologist (JP). For 14 (26.9%) cases, representative haematoxylin and eosin (H&E)-stained slides and unstained sections (3 µm) had been prepared and stored desiccated at 4°C for up to 15 years. For the remaining cases (n = 38), H&E slides and unstained sections (8 µm) were cut immediately prior to RNA extraction.
RNA extraction from FFPE prostate tumor material
Tumor areas representative of the overall Gleason score and adjacent benign areas were identified by a pathologist (JP and TN) and marked directly on the representative H&E-stained section. On average, five 3 µm (previously cut) or 8 µm (freshly cut) unstained sections were deparaffinized using a standard xylene and ethanol procedure prior to macrodissection of prostate tumor and adjacent histologically normal tissue (ADJ NT ). RNA was extracted using the RNeasy FFPE Kit (QIAGEN) or the RecoverAll™ Total Nucleic Acid Isolation Kit for FFPE (ThermoFisher Scientific) as per the manufacturer's instructions except that RNA was eluted in a final volume of 30 µl of nuclease-free water and stored at −80°C. The quantity and quality of FFPE RNA was measured using the Agilent 2100 Bioanalyzer system (RNA 6000 Pico Kit) according to the manufacturer's instructions (Table 1) .
The Ion AmpliSeq™ Transcriptome Human Gene Expression Kit
Gene expression was evaluated using the AmpliSeq™ Transcriptome Human Gene Expression Kit (ThermoFisher Scientific). Complementary DNA (cDNA) was generated with SuperScript ® VILO™ cDNA Synthesis Kit using 10-110 ng of FFPE RNA or 4 ng of total RNA (Table 1) following by library preparation using Ion AmpliSeq technology and the human gene expression core panel to generate barcoded libraries. Libraries were quantified by qPCR using the Ion Library Quantification Kit, diluted to 100 pM and pooled equally, with either eight or six individual samples per pool. Each chip contained at least one lymphoblastic cell line-derived RNA sample as a positive control. In addition, each pilot study contained at least one replicate prostate tissue sample with 25 samples repeated across the eight pilots (Table 1) . Pooled libraries were amplified using emulsion PCR on an Ion Torrent OneTouch2 instrument and enriched following the manufacturer's instructions. Libraries were then loaded onto an Ion P1 chip V2 and sequenced on the Ion Torrent Proton™ sequencing system, using the Ion PI sequencing 200 Kit v3 chemistry. 
Protocol optimization
The first pilot utilized 3 µm tumor tissue slides, which had been stored at 4°C, and run according to the standard manufacturer's instructions for the AmpliSeq™ Kit. For each successive pilot, protocol modifications, such as cDNA synthesis time, starting input concentrations and amplification cycles, were made with the aim of optimizing the quality of the sequencing output data ( Table 2) .
Data analysis
The Ion Torrent Suite v5.02 software was used to map reads. Raw read-count data files were imported into the R environment v3.3.2 and edgeR [20] was used for read-count normalization and differential gene expression (DGE) analysis.
The quality of data output from each sample was assessed according to the (1) total number of mapped reads; (2) percentage of reads that mapped to AmpliSeq target regions (OnTarget%); (3) 
Results
Sample summary
Diagnostic FFPE tumor tissue was available for 52 PrCa cases (TRUS n = 15; TURP n = 37), 26 of which had regions of both tumor and ADJ NT marked for RNA extraction (Table 1) . After RNA extraction, 14 samples (ADJ NT n = 6; cancer n = 8) were not suitable for further analysis due to a small quantity and/or poor quality RNA (<20% of RNA fragments >200 nucleotides) ( Table 1 ). In total, 44 tumor and 20 ADJ NT samples (19 cancer-ADJ NT pairs) from 45 patients were processed over the series of eight pilot studies. Abbreviation: LCL lymphoblastic cell line.
Transcriptome data from FFPE tissue
Protocol optimization
The eight pilot studies consisted of between one and six Ion PI V2 chips ( Table 1 ). As outlined in Table 2 , several protocol changes were implemented targeting both the sample preparation and the Ion AmpliSeq™ Kit protocol. Progressive modifications to Pilots 2-5 were assessed using individual sample measures of the total number of mapped reads, percent of reads mapped to Ion AmpliSeq target regions (OnTarget%), and percent of Ion AmpliSeq target genes with ≥10 read counts (TargetsDetected%), and a comparison of the read-count distribution. Figure 1 shows the total number of mapped reads per sample, which increased steadily with the protocol modifications ( Table 2) . The OnTarget% and TargetsDetected% also improved with subsequent protocol modifications, with notable increases in both measurements from Pilot 5 onward (Fig. 2) Table 1) . The gene read-count distribution was calculated for each of the prostate tissue samples and compared with the median read-count distribution of the 20 cell line-derived RNA samples ( Fig. 3; full results-Supplementary Fig. 1) . A high correlation between prostate and cell line-derived RNA read-count distributions was observed when prostate tissue samples reached >40% of OnTarget% reads, and a similar result was observed for TargetsDetected% (Supplementary Fig. 2 ). These results demonstrate that the protocol changes incorporated at Pilot 5 ( Table 2) generally produced higher quality data that were comparable to those obtained from the cell line-derived RNA samples.
Performance of replicate samples
To further investigate the outcome of the protocol changes implemented in Pilots 1-5, we measured the correlation of gene expression profiles between replicate samples. Across the pilot runs, 25 samples (both tumor and ADJ NT ) were processed at least twice, resulting in 32 within-pilot replicates, including 16 within-chip replicates. Figure 4 shows the correlation coefficient (Pearson's) of replicates increased with successive pilots, with the majority achieving a correlation coefficient >0.9 from Pilot 5 onward. Apart from Pilot 1 samples, even replicates consisting of low OnTarget % and TargetsDetected% had relatively good correlation coefficient scores (>0.8). This is probably due to the fact that only highly expressed genes had been amplified in the poor-quality samples, and although there were very few read counts, they still correlated.
Selection of high-quality samples
Hierarchical cluster analysis was then performed on OnTarget%, TargetsDetected%, and the correlation coefficient between the read-count distributions of the cell linederived RNA and prostate tissue samples (Fig. 5) . Poorquality samples, which had low-quality output for all three measures, clustered separately from two other groups; the first consisting of samples with high-quality output for all three measures, and the second consisting of moderately performing samples with variable outputs across the three quality measures. Based on the hierarchical clustering, samples of higher quality were selected using the following high stringency cutoffs: OnTarget% >60%; TargetsDetected% >50%; and read-count correlation coefficient >0.75 ( Supplementary Fig. 3 ). Using these criteria, 64 samples were classified as high-quality and the majority of these were processed in Pilots 5-8. This optimized protocol is outlined in Fig. 6 . For a less stringent selection of high-quality samples, a single criterion of an OnTarget% >50% could be applied, as even with lower mapped reads and read-count correlation coefficients, these samples clustered with the samples defined as high-quality using the more stringent criteria ( Supplementary Fig. 4 ).
TRUS vs. TURP specimens
The majority of samples used in this study were TURP specimens (n = 78; 75.7%), with TRUS specimens (n = 25; 24.3%) processed in the earlier pilots (1, 2, 3) and in Pilot 8. Fifteen TRUS samples (including six replicates) processed using the optimal protocol in Pilot 8 were classified as highquality based on the more stringent criteria. The four TRUS samples that were classified as poor-quality had comparatively low percentages of RNA fragments >200 nucleotides (5-15%). The fifth TRUS sample was classified as moderate quality but had a comparatively average percentage of total RNA fragments >200 nucleotides (31%), and its replicate sample was classified as high-quality. The only other samples that were not scored as high quality from Pilot 5 onward were ten TURP specimens in Pilot 5 that had <20% of RNA fragments >200 nucleotides. Notably, the highquality TRUS samples from Pilot 8 had a similar distribution of OnTarget%, TargetsDetected%, and read-count correlation measures as the high-quality TURP specimens ( Supplementary Fig. 5 ). Of the high-quality TRUS samples, the cores ranged in length from 17 to 34 mm and the extracted lengths from 5.8 to 17 mm (further information available in Supplementary Table 1) .
Analysis of high-quality samples
The data set defined as high quality included 16 samples that were replicated at least once. Hierarchical cluster analysis resulted in replicate pairs clustering tightly, with the exception of one sample, 06.000.02533 ( Supplementary  Fig. 6 ). To further examine this sample, Pearson's correlation coefficients were calculated for each of the 06.000.02533 replicate pairs and indicated a high correlation of data (>0.8; p < 0.001). Based on these results, we merged the read counts of all replicate samples, which resulted in a final high-quality data set consisting of 41 samples.
To further investigate our high-quality PrCa data set in the context of known differentially expressed genes (DEGs) and results from The Cancer Genome Atlas (TCGA), we performed analysis on TMM normalized data from the 15 ADJ NT and 26 prostate tumor samples. This analysis identified 2630 DEGs (FDR <0.01), of which 1275 were (Fig. 7) . The top five DEGs included ADRA1A, HIF3A, PGM5, PGM5P2, and RRN3P2, which were downregulated in tumor compared with ADJ NT (Fig. 8a) . These five genes are also downregulated in tumor compared with benign tissue in TCGA (data not shown). In addition, several other genes known to be differentially expressed in tumor and ADJ NT were identified within our set of 2630 significantly DEGs, including AMACR [21] , MYC [22, 23] , AOX1 [24] , SCGB3A1 [24] , and HPN [25, 26] (Fig. 8b) .
Discussion
We have demonstrated that RNA derived from archival FFPE diagnostic prostate tissue can be successfully utilized for gene expression profiling using the Ion AmpliSeq Transcriptome Human Gene Expression Kit. Adopting several changes to the protocol, we were able to generate high-quality data from FFPE prostate cancer tissue that was equivalent to cell line-derived RNA.
Our final protocol included several changes to the original workflow, including the use of freshly cut slides for macrodissection; increased tissue section thickness of 8 µm;
RNA extraction using the RecoverAll Total Nucleic Acid Isolation Kit for FFPE (ThermoFisher); 18 target amplification cycles; and processing a maximum of six samples per chip. Using data generated from both the prostate tissue and positive control cell line, we determined that a high-quality sample (appropriate for DGE analysis) was defined by an OnTarget% >60%, a TargetsDetected% >50%, and a readcount correlation coefficient >0.75. Additionally, we have found that samples should have at least 20% of RNA fragments with >200 nucleotides in length before library preparation.
This study has shown that if FFPE specimen slides are freshly sectioned, high-quality gene expression data can be obtained from small amounts of starting tissue (e.g., TRUS prostate specimens), including that from FFPE tissue blocks that have been stored for over a decade. Specimens were collected and processed in several pathology laboratories across the state of Victoria, Australia, from 1992 to 2012. Over this period, collection, fixation, and processing of TRUS and TURP specimens has remained relatively consistent, whereby specimens are placed immediately after collection in buffered formalin and fixed for a maximum of 8 h. Some variation in specimen processing within and between the laboratories is likely given the range Fig. 3 of settings from which these specimens were collected; however, our study also demonstrates that the optimized AmpliSeq protocol is robust to any variations that may have been present over this period of time. Although our study was based on diagnostic PrCa tissue specimens, our protocol using the AmpliSeq Kit can be applied to any small volume FFPE tissue specimen, thus increasing the scope of gene expression studies to cancer biopsy specimens. This is particularly pertinent to prognostic studies, which have previously been limited due to the quantity and quality of diagnostic FFPE biopsy samples.
To estimate the reliability of the gene expression data, we performed DGE analysis on high-quality adjacent benign and prostate tumor samples, resulting in the identification of 2630 significantly DEGs (FDR <0.001). The direction of change in gene expression for our top five DEGs, ADRA1A, HIF3A, PGM5, PGM5P2, and RRN3P2, was the same as that seen in the 499 prostate adenocarcinomas in TCGA. Two of these genes, ADRA1A and HIF3A, have been shown to be involved in prostate cancer biology: stimulation of ADRA1A results in the proliferation of the LNCaP epithelial cell line [27] and HIF3A is hypermethylated in radical prostatectomy tumor cells [24, 28] , resulting in reduced gene expression levels [24] . Several other genes known to be involved in prostate cancer biology (e.g., AMACR, MYC, AOX1, SCGB3A1, and HPN) were also found to be significantly differentially expressed in our tumor samples and in the same direction as observed by prior studies [21] [22] [23] [24] [25] [26] .
Recently, Knudsen et al. applied the Affymetrix Human Exon 1.0 ST GeneChip to 26 FFPE prostate cancer biopsy specimens and observed good correlations between transcriptomic features in the biopsies and matched RP specimens (r = 0.96) [13] . Interestingly, they observed that the correlation of a Decipher prognostic expression signature between matched specimens was not as robust (r = 0.70), and hierarchical clustering and PCA analysis of the data revealed two large clusters based upon the sample origin, i.e., biopsy vs. RP. These differences may be due to progression of the disease, cell transformation due to intermediate treatment, or a reflection of the tumor focus sampled and percentage of tumor epithelial cells present in the samples. One of the limitations of the study by Knudsen et al. is the variation in the amount of tumor cells in the tumor cores or punches, which ranged between 5-70% in the cores and 10-90% in the punches. In addition, some of the biopsy cores had up to 80% of stromal cells. Nonetheless, the gene expression differences between RP and biopsy samples highlight the importance of analyzing biopsy samples in order to develop a panel of prognostic markers that can be applied at diagnosis.
One of the strengths of our study is that regions of tumor and ADJ NT epithelial cells were marked by a pathologist and specific areas of interest were then macrodissected. RNA extracted from these regions were thus enriched for either tumor or ADJ NT cells, thereby reducing the proportion of stromal cells. Another strength of our design was the number of replicate samples, including several run under optimal conditions to determine the robustness of the protocol. We also included both TRUS and TURP specimens, as both form the basis of prostate cancer diagnoses. While the proportion of TRUS samples was low, the distribution of OnTarget%, TargetsDetected%, and read-count correlation measures were similar between high-quality TRUS and TURP specimens. In the current study, we used RNA from the lymphoblastic cell line as a data quality standard. In future studies, it would be valuable to include RNA from paired fresh frozen tumor samples, if available, as a further Fig. 8 Differential expression between FFPE prostate cancer and adjacent benign (ADJ NT ) samples for the A top five most differentially expressed genes ranked by adjusted p values, and B five genes previously shown to be differentially expressed in prostate cancer tissue quality standard for the FFPE specimen data and to determine the effect of formalin fixation and storage on gene expression profiles.
One of the most significant outcomes of this study, and that of Knudsen et al. [13] , is the demonstration that transcriptome data can be obtained from very small quantities of FFPE tumor specimens. This has implications not only for PrCa, but for any cancer where only small amounts of tissue are available for research. It also allows researchers to exploit stored, archival specimens that have previously been underutilized with regard to array-based gene expression studies.
